Avalon GloboCare (ALBT) Competitors $2.57 -0.11 (-4.10%) As of 03:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. MIRA, DARE, PASG, CVKD, SLGL, RLMD, GBIO, BCTX, CALC, and NAIIShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include MIRA Pharmaceuticals (MIRA), Dare Bioscience (DARE), Passage Bio (PASG), Cadrenal Therapeutics (CVKD), Sol-Gel Technologies (SLGL), Relmada Therapeutics (RLMD), Generation Bio (GBIO), Briacell Therap (BCTX), CalciMedica (CALC), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors MIRA Pharmaceuticals Dare Bioscience Passage Bio Cadrenal Therapeutics Sol-Gel Technologies Relmada Therapeutics Generation Bio Briacell Therap CalciMedica Natural Alternatives International MIRA Pharmaceuticals (NASDAQ:MIRA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has preferable valuation & earnings, MIRA or ALBT? MIRA Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.33Avalon GloboCare$1.33M3.65-$7.90M-$19.96-0.13 Is MIRA or ALBT more profitable? MIRA Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -341.08% -272.93% Avalon GloboCare -647.29%N/A -50.13% Does the media refer more to MIRA or ALBT? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 3 mentions for MIRA Pharmaceuticals and 1 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.00 beat MIRA Pharmaceuticals' score of -0.33 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in MIRA or ALBT? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, MIRA or ALBT? MIRA Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Do analysts rate MIRA or ALBT? MIRA Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,076.47%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe MIRA Pharmaceuticals is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMIRA Pharmaceuticals beats Avalon GloboCare on 10 of the 16 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.86M$2.85B$5.45B$8.92BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-0.1320.6327.2720.07Price / Sales3.65290.56428.46118.22Price / CashN/A41.7026.2128.59Price / Book-0.237.427.925.58Net Income-$7.90M-$55.04M$3.17B$248.65M7 Day Performance-7.55%3.70%4.33%7.15%1 Month Performance-25.51%0.35%2.61%8.13%1 Year Performance-67.84%4.79%34.78%21.59% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.6886 of 5 stars$2.57-4.1%N/A-65.9%$4.86M$1.33M-0.135Positive NewsMIRAMIRA Pharmaceuticals2.6065 of 5 stars$1.21-2.8%$14.00+1,057.0%+101.0%$21.07MN/A-2.372DAREDare Bioscience1.5797 of 5 stars$2.39+0.8%$12.00+402.1%-23.8%$20.93M$10K-14.0630PASGPassage Bio2.449 of 5 stars$0.40+20.9%$7.50+1,773.6%-49.7%$20.58MN/A-0.39130Gap UpCVKDCadrenal Therapeutics2.683 of 5 stars$12.05+15.4%$32.00+165.6%N/A$20.53MN/A-1.304Positive NewsGap UpHigh Trading VolumeSLGLSol-Gel Technologies2.6194 of 5 stars$7.40+1.1%$40.00+440.5%-13.3%$20.39M$11.54M-1.5750Gap DownRLMDRelmada Therapeutics4.6055 of 5 stars$0.60-1.6%$5.00+732.9%-79.2%$20.25MN/A-0.2410Gap DownGBIOGeneration Bio2.9464 of 5 stars$0.32+6.6%$7.33+2,191.0%-83.9%$20.14M$19.89M-0.30150Gap DownHigh Trading VolumeBCTXBriacell Therap2.3248 of 5 stars$2.94-0.7%$32.00+988.4%-80.8%$20.06MN/A-0.358CALCCalciMedica3.0706 of 5 stars$1.60+11.9%$18.00+1,025.0%-61.8%$19.98MN/A-1.0330NAIINatural Alternatives International1.0158 of 5 stars$3.28+1.9%N/A-42.1%$19.90M$113.80M-2.36290Positive NewsGap Up Related Companies and Tools Related Companies MIRA Pharmaceuticals Competitors Dare Bioscience Competitors Passage Bio Competitors Cadrenal Therapeutics Competitors Sol-Gel Technologies Competitors Relmada Therapeutics Competitors Generation Bio Competitors Briacell Therap Competitors CalciMedica Competitors Natural Alternatives International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts